TP53 and neoplasm: Although the COMI tumor has a low expression level of the TP53 gene as assessed by quantitative polymerase chain reaction (qPCR)12, its TP53 gene sequence is wild type thus making possible that the residual TP53 activity is sufficient to fade the in vivo radiosensitization response to KU60019.